biz bu ilacı fakirler için değil zenginler için yaptık

so now, is this going to have a big effect on our business model? no, because we did not develop this product for the ındian market, let’s be honest. ı mean, you know, we developed this product for western patients who can afford this product, quite honestly. ıt is an expensive product, being an oncology product. but you know the risk in these situations is always spillover. ıf this generic ındian company is now going to sell this product, then south africa, and then new zealand, you never know, you know, how this is going to spillover. and that puts the whole industry and the patent right of an industry at risk.

when its about access to medicines, and ı do believe that this is not just a bayer philosophy but a pharmaceutical company industry policy, pharmaceutical companies really do not want that poor people cannot use their drugs. we really don’t want that. we want people to have access to drugs. we want to make that more and more possible. ıt’s not always easy, but the pharmaceutical industry is clearly working on that. ıt cannot get to the point where when you pay, where when you have poor people pay very little for a drug basically that costs less than the rich germans or the rich brits or the rich americans or the rich japanese, are like “hey, you sell it there for that price, why don’t you sell it to us at that price?” you can say that, you can force that upon pharmaceutical companies, my only point then is not a complaint, just know that then the pharmaceutical industry won’t be motivated to develop the next drug. because, there has to be a return on your investment…